NASDAQ:ZURA Zura Bio (ZURA) Stock Price, News & Analysis $3.89 +0.12 (+3.18%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.78▼$3.9450-Day Range$3.27▼$5.9952-Week Range$2.00▼$7.63Volume258,976 shsAverage Volume274,245 shsMarket Capitalization$247.99 millionP/E RatioN/ADividend YieldN/APrice Target$19.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Zura Bio alerts: Email Address Zura Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside407.7% Upside$19.75 Price TargetShort InterestBearish5.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 4 Articles This WeekInsider TradingAcquiring Shares$496,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.53) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.42 out of 5 starsMedical Sector586th out of 936 stocksBiological Products, Except Diagnostic Industry92nd out of 154 stocks 3.6 Analyst's Opinion Consensus RatingZura Bio has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZura Bio has only been the subject of 3 research reports in the past 90 days.Read more about Zura Bio's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.41% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Zura Bio has recently increased by 152.08%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZura Bio does not currently pay a dividend.Dividend GrowthZura Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZURA. Previous Next 2.9 News and Social Media Coverage News SentimentZura Bio has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Zura Bio this week, compared to 1 article on an average week.Search Interest12 people have searched for ZURA on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows10 people have added Zura Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zura Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $496,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders15.80% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zura Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Zura Bio are expected to decrease in the coming year, from ($0.53) to ($0.74) per share.Price to Book Value per Share RatioZura Bio has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zura Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.Click here to learn more. About Zura Bio Stock (NASDAQ:ZURA)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.Read More ZURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZURA Stock News HeadlinesJuly 22, 2024 | americanbankingnews.comAnalyzing Scilex (NASDAQ:SCLX) & Zura Bio (NASDAQ:ZURA)July 17, 2024 | americanbankingnews.comZura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by BrokeragesJuly 26, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.July 12, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in July 2024June 14, 2024 | businesswire.comZura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024June 6, 2024 | businesswire.comZura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and ImmunologyJune 3, 2024 | businesswire.comZura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024May 29, 2024 | businesswire.comZura Bio Announces Participation in June Investor ConferencesJuly 26, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.May 24, 2024 | msn.comZura Bio files to sell 41.6M Class A ordinary shares for holdersMay 24, 2024 | investorplace.com3 Penny Stocks to Buy Now: May 2024May 10, 2024 | finance.yahoo.comZura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic DevelopmentsMay 9, 2024 | investorplace.comZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024May 9, 2024 | finance.yahoo.comZura Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 4, 2024 | msn.comPiper Sandler Initiates Coverage of Zura Bio (ZURA) with Overweight RecommendationMay 3, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Zura Bio (ZURA)May 1, 2024 | finance.yahoo.comZura Bio Limited (ZURA)April 28, 2024 | 247wallst.comThese Biotechs and IPOs Inspire Big Insider BuyingSee More Headlines Receive ZURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZURA CUSIPN/A CIK1855644 WebN/A Phone858-247-0520FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$19.75 High Stock Price Target$26.00 Low Stock Price Target$10.00 Potential Upside/Downside+407.7%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-64.56% Return on Assets-50.33% Debt Debt-to-Equity RatioN/A Current Ratio6.17 Quick Ratio6.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.85 per share Price / Book2.10Miscellaneous Outstanding Shares63,750,000Free Float36,706,000Market Cap$247.99 million OptionableNot Optionable Beta0.15 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Verender S. Badial (Age 51)Chief Financial Officer Comp: $374.92kDr. Michael D. Howell Ph.D. (Age 47)Chief Scientific Officer & Head of Translational Medicine Comp: $1.97MMs. Kimberly Ann Davis (Age 56)Chief Legal Officer & Secretary Comp: $2.16MMr. Robert Lisicki (Age 56)President, CEO & Director Dr. Gary Whale Ph.D. (Age 50)Chief Technology Officer Ms. Theresa Lowry (Age 50)Chief Human Resources Officer Mr. David BradyHead of Business DevelopmentDr. Kiran Nistala MBBS (Age 51)Ph.D., Chief Medical Officer & Head of Development More ExecutivesKey CompetitorsMesoblastNASDAQ:MESO4D Molecular TherapeuticsNASDAQ:FDMTCARGO TherapeuticsNASDAQ:CRGXTectonic TherapeuticNASDAQ:TECXScholar RockNASDAQ:SRRKView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 6,412 shares on 7/26/2024Ownership: 0.074%Van Amstel Arnout PloosBought 80,000 shares on 5/17/2024Total: $496,000.00 ($6.20/share)Affinity Asset Advisors LLCBought 450,009 shares on 5/15/2024Ownership: 1.044%Amit MunshiBought 159,744 shares on 4/22/2024Total: $499,998.72 ($3.13/share)Michael HowellBought 7,987 shares on 4/22/2024Total: $24,999.31 ($3.13/share)View All Insider TransactionsView All Institutional Transactions ZURA Stock Analysis - Frequently Asked Questions How have ZURA shares performed this year? Zura Bio's stock was trading at $4.67 at the beginning of the year. Since then, ZURA shares have decreased by 16.7% and is now trading at $3.89. View the best growth stocks for 2024 here. How were Zura Bio's earnings last quarter? Zura Bio Limited (NASDAQ:ZURA) issued its quarterly earnings data on Thursday, May, 9th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.21. Who are Zura Bio's major shareholders? Zura Bio's top institutional investors include Bank of New York Mellon Corp (0.07%). Insiders that own company stock include Van Amstel Arnout Ploos, Michael Howell and Kiran Nistala. View institutional ownership trends. How do I buy shares of Zura Bio? Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZURA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zura Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZURA Stock Alerts